Volume 64, Issue 2, Pages (August 2003)

Slides:

Advertisements

Similar presentations

Volume 67, Issue 2, Pages (February 2005)

Advertisements

Volume 63, Issue 2, Pages (February 2003)

Volume 54, Issue 2, Pages (August 1998)

Increased cGMP phosphodiesterase activity mediates renal resistance to ANP in rats with bile duct ligation Xi-Ping Ni, Massy Safai, David G. Gardner,

Volume 79, Issue 6, Pages (March 2011)

Volume 62, Issue 2, Pages (August 2002)

Volume 62, Issue 1, Pages (July 2002)

Volume 58, Issue 5, Pages (November 2000)

Volume 64, Issue 6, Pages (December 2003)

Volume 84, Issue 2, Pages (August 2013)

Volume 80, Issue 3, Pages (August 2011)

Mycophenolate mofetil treatment for primary glomerular diseases

Yiping Wang, Yuet-Ching Tay, David C.H. Harris Kidney International

Volume 83, Issue 5, Pages (May 2013)

Peripheral detection of S100β during cardiothoracic surgery: what are we really measuring? Vincent Fazio, MS, Sunil K Bhudia, MD, Nicola Marchi, PhD,

Kidney involvement in a nongenetic rat model of type 2 diabetes

Hua Liu, Steven A. Bigler, Jeffrey R. Henegar, Radhakrishna Baliga

Volume 67, Issue 4, Pages (April 2005)

Volume 54, Issue 2, Pages (August 1998)

Volume 64, Issue 5, Pages (November 2003)

Volume 64, Issue 2, Pages (August 2003)

Volume 73, Issue 4, Pages (February 2008)

Volume 67, Issue 2, Pages (February 2005)

Volume 68, Issue 1, Pages (July 2005)

Evidence for low-density lipoprotein–induced expression of connective tissue growth factor in mesangial cells Mimi Sohn, Yan Tan, Richard L. Klein, Ayad.

Volume 70, Issue 3, Pages (August 2006)

Volume 54, Issue 6, Pages (January 1998)

Measurement of matrilin-3 levels in human serum and synovial fluid using a competitive enzyme-linked immunosorbent assay J.-B. Vincourt, P. Gillet, A.-C.

Volume 56, Issue 4, Pages (October 1999)

PPARα agonist fenofibrate improves diabetic nephropathy in db/db mice

Volume 54, Issue 2, Pages (August 1998)

Volume 68, Issue 2, Pages (August 2005)

Volume 74, Issue 7, Pages (October 2008)

The need for reliable serum parathyroid hormone measurements

Volume 67, Issue 2, Pages (February 2005)

Volume 54, Issue 5, Pages (November 1998)

Volume 72, Issue 3, Pages (August 2007)

Volume 79, Issue 10, Pages (May 2011)

Volume 60, Issue 1, Pages (July 2001)

Volume 74, Issue 5, Pages (September 2008)

17-β Estradiol attenuates streptozotocin-induced diabetes and regulates the expression of renal sodium transporters S. Riazi, C. Maric, C.A. Ecelbarger

Volume 86, Issue 5, Pages (November 2014)

Volume 61, Issue 3, Pages (March 2002)

Comparison of three methods to quantify urinary aquaporin-2 protein

Volume 80, Issue 2, Pages (July 2011)

Albumin-like material in urine

Volume 56, Issue 2, Pages (August 1999)

Volume 68, Issue 2, Pages (August 2005)

John H. Wiessner, Linda Y. Hung, Neil S. Mandel Kidney International

Volume 69, Issue 12, Pages (June 2006)

Volume 69, Issue 3, Pages (February 2006)

Volume 77, Issue 8, Pages (April 2010)

Volume 69, Issue 10, Pages (May 2006)

Volume 78, Issue 8, Pages (October 2010)

Volume 75, Issue 3, Pages (February 2009)

Small heat shock protein alteration provides a mechanism to reduce mesangial cell contractility in diabetes and oxidative stress Marjorie E. Dunlop,

Volume 56, Pages S178-S181 (July 1999)

Volume 69, Issue 8, Pages (April 2006)

Volume 63, Issue 6, Pages (June 2003)

Volume 60, Issue 5, Pages (November 2001)

The course of the remnant kidney model in mice

Volume 56, Issue 1, Pages (July 1999)

Volume 67, Issue 6, Pages (June 2005)

Volume 53, Issue 4, Pages (April 1998)

Volume 64, Issue 2, Pages (August 2003)

Volume 62, Issue 5, (November 2002)

Volume 58, Issue 2, Pages (August 2000)

Volume 62, Issue 5, Pages (November 2002)

Plasma concentration and urinary excretion of N-terminal proatrial natriuretic peptides in patients with kidney diseases Martina Franz, Wolfgang Woloszczuk,

Volume 79, Issue 10, Pages (May 2011)

Presentation transcript:

Volume 64, Issue 2, Pages 451-458 (August 2003) Urinary CCN2 (CTGF) as a possible predictor of diabetic nephropathy: Preliminary report Bruce L. Riser, Pedro Cortes, Mark Denichilo, Poornima V. Deshmukh, Parminder S. Chahal, Ali K. Mohammed, Jerry Yee, Dorothy Kahkonen Kidney International Volume 64, Issue 2, Pages 451-458 (August 2003) DOI: 10.1046/j.1523-1755.2003.00130.x Copyright © 2003 International Society of Nephrology Terms and Conditions

Fig 1 Rat urinary CCN2 and the influence of diabetes. Concentrations in two consecutive 24-hour urine samples were measured by enzyme-linked immunosorbent assay (ELISA) and normalized to the amount of creatinine in the same sample. All CCN2 values (mean log ± SE) in the experimental group (N = 12) were significantly different than those in the control group (N = 6) at the corresponding periods (P < 0.0001). Within each group, CCN2 levels decreased significantly over time. *P < 0.0006 versus 3weeks; **P < 0.0001 versus 11weeks; ***P < 0.032 versus 8weeks and 11weeks. Kidney International 2003 64, 451-458DOI: (10.1046/j.1523-1755.2003.00130.x) Copyright © 2003 International Society of Nephrology Terms and Conditions

Fig 2 Urinary CCN2 albumin levels in streptozotocin (STZ)-diabetic and control rats. Concentrations of albumin were measured following urine collection as described in Fig. 1. The value (mean ± SE.) of albumin in diabetic animals (N = 12) was significantly greater at 32weeks than the corresponding control (N = 6) group (P = 0.042). Kidney International 2003 64, 451-458DOI: (10.1046/j.1523-1755.2003.00130.x) Copyright © 2003 International Society of Nephrology Terms and Conditions

Fig 3 Measurement of urinary CCN2 from patients and healthy volunteers. Urinary CCN2 levels were measured by enzyme-linked immunosorbent assay (ELISA). Each bar represents the determination from an individual patient sample run in triplicate. The dashed line indicates the mean value for all healthy volunteers. Kidney International 2003 64, 451-458DOI: (10.1046/j.1523-1755.2003.00130.x) Copyright © 2003 International Society of Nephrology Terms and Conditions

Fig 4 Identification of urinary CCN2 protein in a healthy donor and the stability of added recombinant molecule. Urine was collected from a healthy donor who demonstrated detectable CCN2 level by enzyme-linked immunosorbent assay (ELISA). The sample was divided into five, 25mL aliquots. Increasing amounts of recombinant human CCN2 (rhCCN2) (25 to 750ng) were added to four of the aliquots. As a control, buffer only was added to the fifth aliquot. Immunoblotting was performed using CCN2-specific antibody. Kidney International 2003 64, 451-458DOI: (10.1046/j.1523-1755.2003.00130.x) Copyright © 2003 International Society of Nephrology Terms and Conditions

Fig 5 Immunoblot analysis of urinary CCN2 from healthy volunteers and diabetic patients. Representative urine samples from four unselected patients (lanes A to D) collected during routine visits and three healthy volunteers (lanes E to G) were processed and examined for CCN2 by immunoblotting using CCN2-specific antibody. Kidney International 2003 64, 451-458DOI: (10.1046/j.1523-1755.2003.00130.x) Copyright © 2003 International Society of Nephrology Terms and Conditions